“Time Off for Clinical Trials," launched on Nov. 20, sees six of BioNJ’s biggest members—Amicus Therapeutics, Bristol Myers ...

Alzheimer’s and Huntington’s patients do have different symptoms and disease biology, but that made no difference to the ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third ...

Medtronic has reported revenue gains across several of its medical device franchises, leading the company to nudge up its ...

Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...